Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — UniCredit Kepler Cheuvreux 23rd German Corporate Conference 2024

56 slides from Fresenius SE & Co. KGaA's conference presentation, Jan 15, 2024

  1. Slide 1: #FutureFresenius – Advancing Patient Care

    #FutureFresenius – Advancing Patient Care UniCredit Kepler Cheuvreux 23rd German Corporate Conference - Frankfurt January 15, 2024

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive

  3. Slide 3: Company overview

    1 Company overview 2 Strategic update 3 Business update Q3/23 4 Financial priorities & outlook FY/23 5 Attachments

  4. Slide 4: A global leader in healthcare products and services

    A global leader in healthcare products and services Long-term opportunities in revenue in growing, (FY/2022) non-cyclical €21.5 bn Global markets presence in 100+ countries 100 + Employees Strong financial worldwide performance (as of Sep. 30, and cash flow 2023) 190,000+ Leading generation market p

  5. Slide 5: Global trends offer growth opportunities for Fresenius

    Global trends offer growth opportunities for Fresenius Increasing Managing health data >10% healthcare spend More than 30% of global data is generated by Life Science and Generic drugs More than 10% of global GDP will be 97% Healthcare and only 2% of data save the US spent on healthcare in 20301 of

  6. Slide 6: Our purpose for #FutureFresenius – Advancing Patient Care

    Our purpose for #FutureFresenius – Advancing Patient Care UniCredit Kepler Cheuvreux 23rd German Corporate Conference © Fresenius SE & Co. KGaA Investor Relations 6

  7. Slide 7: At the heart of healthcare

    At the heart of healthcare 30+ studies in parenteral and Breakthrough technology infusion system enteral nutrition Device supplier for 1/3rd of FDA/EMA- 3 multiproduct biologic drug approved CAR-T cell therapies Better substance facilities #2 for plasma collection Treatments Pipeline of 10+ biosimil

  8. Slide 8: #FutureFresenius – Operating Companies and Investment Companies

    #FutureFresenius – Operating Companies and Investment Companies #FutureFresenius Operating Companies Investment Companies Profitability optimization and growth Financial value management Dialysis Project Healthcare products Healthcare services provision business for critically and chronically ill pa

  9. Slide 9: Therapy-focused platforms – Bringing the future of healthcare to patients

    Therapy-focused platforms – Bringing the future of healthcare to patients Specialized Leverage at-scale capabilities and capacities for (BIO)PHARMA PLATFORM leading (bio-) pharmaceutical & nutrition products Targeted Empower cutting-edge medical technology MEDTECH PLATFORM solutions in critical care

  10. Slide 10: Fresenius Kabi – Accelerating our growth, driving performance

    Fresenius Kabi – Accelerating our growth, driving performance Highly specialized, essential healthcare products with balanced market reach €3.8B €2.4B €1.4B €0.2B Healthcare services Pharma Nutrition MedTech Biopharma along the care continuum • Strong focus on key growth vectors • Strengthening resi

  11. Slide 11: Fresenius Helios – Powerful set of care provision assets

    Fresenius Helios – Powerful set of care provision assets Leading healthcare services delivering value for >24 million patients yearly €7.0B €4.4B Healthcare products for critically and chronically ill patients • Continuing stable margin delivery • Increased focus on return on capital and cash flow •

  12. Slide 12: Fresenius share & shareholder structure

    Fresenius share & shareholder structure Share price development LTM (%) Analyst recommendations Click to view our interactive share price tool Click to view downloadable set of the consensus data 140 FRE 120 DAX Equal-weight/Hold/ Accumulate/Add/Buy/ 100 Neutral 28% Outperform/Overweight STOXX Europ

  13. Slide 13: Progressive dividend policy

    Progressive dividend policy Dividend Stable Progressive dividend policy • Commitment to delivering Payout ratio1 attractive and predictable 24% 24% 27% 28% 30% shareholder return €0.92 €0.92 €0.88 €0.84 €0.75 • Dividend for FY/22 remained on prior-year level despite challenging environment • Dividen

  14. Slide 14: Strategic update

    1 Company overview 2 Strategic update 3 Business update Q3/23 4 Financial priorities & outlook FY/23 5 Attachments

  15. Slide 15: #FutureFresenius – ReSet delivered, pacing ReVitalization

    #FutureFresenius – ReSet delivered, pacing ReVitalization ✓ FMC deconsolidation to be ✓ Clear ambitions – F3 sets framework completed by December Structural Operating Companies Fresenius Group Investment Companies simplification FSE expectation as major shareholder EBIT margin 14 – 17% 9 – 11% 10 –

  16. Slide 16: New, more rigorous F³ – Fresenius Financial Framework

    New, more rigorous F³ – Fresenius Financial Framework Fresenius Group Operating Companies Investment Companies FSE expectation as major shareholder EBIT 14 – 17% 9 – 11% 10 – 14% 4 – 6% margin Targeting upper end of range by 2026 Organic 4 – 7% 3 – 5% revenue growth CAPITAL EFFICIENCY CAPITAL STRUCT

  17. Slide 17: #FutureFresenius – Delivering on our promises; quarter on quarter

    #FutureFresenius – Delivering on our promises; quarter on quarter Deliver 2023 and upgrade performance 2024+ FMC deconsolidation approved ▪ Deconsolidation of FMC created “currency” Kabi and Helios: ▪ Consistent strong performance of Operating Companies Focus, transparency, performance ▪ Structural

  18. Slide 18: #FutureFresenius - REVITALIZE

    #FutureFresenius - REVITALIZE 2022 2023 2024 2025 2026 2027 2030+ RE JUVENATE RE IMAGINE ✓ RE VITALIZE RE SET Optimize portfolio & Pursue platform-driven Shape the future refine operating model growth opportunities of healthcare UniCredit Kepler Cheuvreux 23rd German Corporate Conference © Fresenius

  19. Slide 19: Business update Q3/23

    1 Company overview 2 Strategic update 3 Business update Q3/23 4 Financial priorities & Outlook FY/23 5 Attachments

  20. Slide 20: #FutureFresenius – 2023 outlook improved

    Q3/23: #FutureFresenius momentum continuing Kabi and Helios deliver strong performance Cost savings delivery ahead of schedule Simplification advanced: FMC deconsolidation effective December VAMED EBIT positive Divestment program advancing #FutureFresenius – 2023 outlook improved UniCredit Kepler Ch

  21. Slide 21: Group EBIT outlook improved

    Kabi and Helios: Consistent strong delivery O P E R AT I N G C O M PA N I E S Q1/23 Q2/23 Q3/23 REVENUE ORG. +7% +8% +7% EBIT -4% +5% +6% Group EBIT REVENUE ORG. +5% +7% +5% outlook EBIT +2% +3% +8% improved I N VE S T M E N T C OM PA N Y for FY/23 REVENUE ORG. +13% -7% +13% EBIT -€27m -€20m €10m Wi

  22. Slide 22: Kabi and Helios at top-end of structural growth band

    Kabi and Helios at top-end of structural growth band 14 - 17 9-11 EBIT (MARGIN) €289m 14.3% €239m 8.1% REVENUE 4 - 7 3-5 (ORG. GROWTH) €2.0bn +7% €3.0bn +5% KEY ▪ Strong organic revenue growth driven ▪ Strong organic revenue growth at MESSAGES by outstanding 12% increase in top-end of growth band Nu

  23. Slide 23: Improving debt profile: A top priority

    Improving debt profile: A top priority Key efforts MORE FLEXIBILITY Cost savings FY/23 savings target achieved Organic growth Top-end of growth band LOWER EXPENSES Operating gains Operating companies in margin band YTD HIGHER Divestments of EPS non-core assets Divestments advancing; hospital exit in

  24. Slide 24: Advancing patient care – strong partnerships, launches and recognition

    Advancing patient care – strong partnerships, launches and recognition RECENT HIGHLIGHTS Fresenius Kabi signed agreement with Virginia Oncology Associates to deliver Ivenix Infusion System mAbxience and Abbott enter strategic partnership Fresenius Kabi launches Tyenne®, the first approved tocilizuma

  25. Slide 25: Fresenius Kabi Named Vizient Supplier Partner of the Year

    Advancing patient care – Fresenius Kabi Named Vizient Supplier Partner of the Year Vizient’s members include more than half of all U.S. acute care health systems and 97% of U.S. academic medical centers. This is their most prestigious supplier award. “Fresenius Kabi has demonstrated how suppliers ca

  26. Slide 26: Advancing patient care – delivering quality and innovative healthcare

    Advancing patient care – delivering quality and innovative healthcare RECENT HIGHLIGHTS Opening of the Quirónsalud Valdebebas Medical Center in Madrid with 18 specialties, state-of-the-art facilities and a highly qualified team Quirónsalud Málaga launches an Advanced Clinical Research Program with s

  27. Slide 27: Five Quirónsalud hospitals recognized as World's Best Specialized Hospitals 2024

    Five Quirónsalud hospitals recognized as “World’s Best Specialized Hospitals 2024” Selected specialities shown UniCredit Kepler Cheuvreux 23rd German Corporate Conference © Fresenius SE & Co. KGaA Investor Relations 27

  28. Slide 28: Q3/23 – Strong Group performance paced by Kabi and Helios

    Q3/23 – Strong Group performance paced by Kabi and Helios ▪ Start of IFRS 5 application in Q3/23 – €519m FMC only included below EBIT €5.5bn ▪ Strong revenue growth driven by Operating +6% +10% Companies and Vamed ▪ EBIT growth reflects strong performance of Operating Companies; Vamed with operation

  29. Slide 29: Fresenius Kabi: Strong growth and margin momentum

    Fresenius Kabi: Strong growth and margin momentum Q3/23 results QUARTERLY FINANCIALS MAIN DEVELOPMENTS 2,100 ▪ Organic revenue growth of 7% at top-end of structural growth band ▪ Growth Vectors contributing 14.5% 14.2% 14.3% 2,000 13.5% EBIT combined 12% organic revenue Margin growth (MedTech: 8%; N

  30. Slide 30: Fresenius Helios: Usual summer effect but strong YoY improvement

    Fresenius Helios: Usual summer effect but strong YoY improvement Q3/23 results QUARTERLY FINANCIALS MAIN DEVELOPMENTS 3,200 ▪ Consistent strong organic revenue 11.7% growth YTD at top-end of structural 3,000 10.0% growth band ▪ Performance at Helios Germany 10.1% 8.1% driven by solid activity levels

  31. Slide 31: Fresenius Vamed: Back to positive operating performance

    Fresenius Vamed: Back to positive operating performance Q3/23 results QUARTERLY FINANCIALS TRANSFORMATION UPDATE 800 ▪ Revenue growth in Q3 driven by both Service as well as Project business ▪ Turnaround in EBIT led by High-End 600 Services and Health Facility Operations 1.5% EBIT ▪ Restructuring me

  32. Slide 32: Cost savings program delivering more quickly than forecasted

    Cost savings program delivering more quickly than forecasted PLANNED UNTIL 2025 FOCUS ON 2023 Cost savings | EBIT view ▪ Focus on Fresenius Group Thereof FMC excl. FMC ~€1,000m Cost savings program is ~€450m ✓~€430m delivered ▪ delivering on 2023 targets – €500m in Q1-3 and beyond ~€650m ✓ ~€289m ~€

  33. Slide 33: Operating cash flow drives Q3/23

    Operating cash flow drives Q3/23 €m Q3/23 Q3/22 Q3/23 Q3/22 ▪ Q3 OCF from continuing LTM LTM operations (excl. FMC) increased by 8% over prior- OCF - continuing operations 648 598 2,084 1,886 year quarter % OCF Margin 11.7% 11.1% 9.3% 8.9% ▪ Kabi: strong OCF develop- ment driven by operating Capex -

  34. Slide 34: Financial priorities & outlook

    1 Company overview 2 Strategic update 3 Business update Q3/23 4 Financial priorities & outlook 5 Attachments

  35. Slide 35: Strong balance sheet is a key pillar of #FutureFresenius

    Strong balance sheet is a key pillar of #FutureFresenius: Debt reduction a priority for 2024 and beyond CREDIT RATINGS Stringent capital allocation and focus on cash flow Standard & Poor’s BBB Outlook: negative are key Fitch BBB- Outlook: stable  Improved credit outlook by Fitch is strong testament

  36. Slide 36: Outlook for FY/23 improved

    Outlook for FY/23 improved Fresenius Group Revenue growth excluding FMC (organic): EBIT (cc growth) excluding FMC: Mid-single-digit growth Broadly flat development (Previously: Broadly flat-to-mid-single-digit decline) Operating Companies Investment Companies ▪ Mid-single-digit ▪ With adoption of IF

  37. Slide 37: FMC: Accounting effects in Q3/23 due to IFRS 5 application

    FMC: Accounting effects in Q3/23 due to IFRS 5 application 2023 2023 REGISTRATION OF JULY 14: SEP. 30: LEGAL FORM IN AT EQUITY EGM Q3 COMMERCIAL REGISTER ACCOUNTING ▪ Change of legal form ▪ Subsequent measurement ▪ Expected to be effective by ▪ Ongoing at equity approved by shareholders under IFRS 5

  38. Slide 38: 2023 Targets for Environment, Social, Governance (ESG) KPIs

    2023 Targets for Environment, Social, Governance (ESG) KPIs Targets aligned with Management Board Compensation Short-term Incentive (STI) 2023 Net Promoter Score (NPS) is a Critical and major Number of quality indicators Degree of patient satisfaction KPI that ensures that FMC observations from regu

  39. Slide 39: Attachments

    = FRESENIUS Attachments

  40. Slide 40: FY/23 – Other financial KPIs for Fresenius Group

    FY/23 – Other financial KPIs for Fresenius Group With adoption of IFRS 5 – Guidance to be provided ex FMC only: Q1-3/23 (ex FMC) Profitability Interest expense €300m Around the middle of the €400 to €440m range Tax rate 25.2% Between 25 to 26% CAPEX 4.4% Around 5% Capital Allocation CCR LTM 0.9 Belo

  41. Slide 41: Capital efficiency and returns

    Capital efficiency and returns ROIC CCR1 NET DEBT/EBITDA2 10% 1.4 1.3 4.5 x 1.2 4.19 9% 1.2 1.1 1.1 1.1 4.03 3.96 8% Q3/22: 5.7% 4.0 x 3.80 1.0 6.7 6.5 3.61 7% 5.9 0.8 3.51 3.88 5.6 0.9 0.9 0.9 0.9 3.44 3.79 6% 5.2 0.7 3.5 x 3.65 5.0 5.0 0.6 5% 5.1 0.4 Q3/22: 0.7 Q3/22: 3.94 4% 4.8 4.6 3.0 x 3% 0.2

  42. Slide 42: Fresenius Group: Revenue Q1-Q3/23

    Fresenius Group: Revenue Q1-Q3/23 Revenue by Region Revenue by Business Segment Latin America and Others 8% Fresenius Helios Fresenius Kabi Asia-Pacific 55% 36% 8% €16.6 bn €16.6 bn North America 12% Europe 72% Fresenius Vamed 9% Revenue Q1-3/2023 UniCredit Kepler Cheuvreux 23rd German Corporate Con

  43. Slide 43: Fresenius Kabi: Q3/23 & Q1-3/23 Organic Revenue Growth by Product Group

    Fresenius Kabi: Q3/23 & Q1-3/23 Organic Revenue Growth by Product Group Δ YoY Δ YoY €m Q3/23 organic Q1-3/23 organic MedTech 369 8% 1,113 9% Nutrition 587 9% 1,803 10% Biopharma 111 71% 264 59% Growth Vectors1 1,067 12% 3,180 11% Pharma 941 1% 2,833 3% (IV Drugs & Fluids) Corporate 13 -- 0 -- Total

  44. Slide 44: Fresenius Kabi: Q3/23 & Q1-3/23 EBIT(DA) development

    Fresenius Kabi: Q3/23 & Q1-3/23 EBIT(DA) development €m Q3/23 Δ YoY cc Q1-3/23 Δ YoY cc Total EBITDA 406 6% 1,209 4% Margin 20.1% +90 bps 20.1% -10 bps Growth Vectors1 104 25% 288 +4% Margin 9.8% +180 bps 9.1% -30 bps Pharma (IV Drugs & Fluids) 200 9% 603 7% Margin 21.3% +150 bps 21.3% +90 bps Corpo

  45. Slide 45: Fresenius Helios: Q3/23 & Q1-3/23 Key Financials

    Fresenius Helios: Q3/23 & Q1-3/23 Key Financials €m Q3/23 Δ YoY cc Q1-3/23 Δ YoY cc Total revenue 2,953 5%1 9,132 6%1 Thereof Helios Germany 1,800 4%1 5,451 3%1 Thereof Helios Spain 1,088 5%1 3,481 9%1 Thereof Helios Fertility 64 13%1 198 13%1 Total EBIT 239 8% 861 4% Margin 8.1% +30 bps 9.4% -20 bp

  46. Slide 46: Fresenius Helios: Key Metrics

    Fresenius Helios: Key Metrics Q1-3/23 FY/22 Δ Helios Germany Hospitals 86 87 -1% - Acute care hospitals 83 84 -1% Beds 29,993 30,352 -1% - Acute care hospitals 29,427 29,786 -1% Admissions 4,143,525 5,508,158 - patients treated in hospital 854,118 1,084,676 - patients treated as outpatient 3,289,407

  47. Slide 47: Fresenius Vamed: Q3/23 & Q1-3/23 Key Financials

    Fresenius Vamed: Q3/23 & Q1-3/23 Key Financials €m Q3/23 Δ YoY cc Q1-3/23 Δ YoY cc Total revenue 647 +13% 1,761 7% Thereof organic revenue +13% 6% Project business 191 24% 426 5% Service business 456 9% 1,335 7% Total EBIT1 10 0% -37 -- Order intake2 40 -74% 262 -61% Order backlog2 2,9083 -22%4 1 Be

  48. Slide 48: Fresenius Group: Calculation of Noncontrolling Interests

    Fresenius Group: Calculation of Noncontrolling Interests €m Q1-3/23 Q1-3/22 Earnings before tax and noncontrolling interests 1,328 1,470 Taxes -334 -326 Noncontrolling interests, thereof -46 -72 Fresenius Kabi -47 -52 Fresenius Helios -14 -14 Fresenius Vamed -2 -3 Fresenius Vamed’s 23% external owne

  49. Slide 49: Fresenius Group: Cash Flow

    Fresenius Group: Cash Flow €m Q3/23 Q3/23 LTM Q3 LTM Margin Δ YoY Operating Cash Flow – 648 2,084 9.3% 8% continuing operations Capex (net) -272 -1,126 -5.0% 22% Free Cash Flow – 376 958 4.3% 0% continuing operations (before acquisitions, dividends and lease liabilities) Acquisitions (net) -181 -237

  50. Slide 50: Fresenius Group: Reconciliation adjusted Free Cash Flow for CCR

    Fresenius Group: Reconciliation adjusted Free Cash Flow for CCR €m Q3/23 Q3/22 Q1-3/23 LTM Q1-3/22 LTM Operating Cash Flow 648 598 2,084 1,886 Capex (net) -272 -223 -1,126 -1,092 Free Cash Flow 376 375 958 794 (before acquisitions and dividends) Special items (net income before minorities) +35 +53 +

  51. Slide 51: Cash Flow development Q3/23

    Cash Flow development Q3/23 Operating Cash Flow Capex (net) Free Cash Flow1 €m Q3/23 Q3/22 Q3/23 Q3/22 Q3/23 Q3/22 Q3/23 Q3/22 Q3/23 Q3/22 Q3/23 Q3/22 Margin Margin Margin Margin Margin Margin 380 301 18.8% 14.5% -110 -118 -5.4% -5.7% 270 183 13.4% 8.8% 208 353 7.0% 12.5% -143 -90 -4.8% -3.2% 65 263

  52. Slide 52: Cash Flow development Q3/23 LTM

    Cash Flow development Q3/23 LTM Operating Cash Flow Capex (net) Free Cash Flow1 €m Q3/23 Q3/22 Q3/23 Q3/22 Q3/23 Q3/22 Q3/23 Q3/22 Q3/23 Q3/22 Q3/23 Q3/22 LTM LTM Margin Margin LTM LTM Margin Margin LTM LTM Margin Margin 879 878 10.9% 11.5% -472 -492 -5.8% -6.4% 407 386 5.1% 5.1% 1,333 1,020 11.0% 8

  53. Slide 53: Revenue by Business Segment – FX, Acquisitions/Divestitures Effects Q3/23

    Revenue by Business Segment – FX, Acquisitions/Divestitures Effects Q3/23 Growth at Currency Growth at Divesti- actual translation constant Organic Acquisi- tures/ €m Q3/23 Q3/22 rates effects rates growth tions Others Fresenius Kabi 2,021 2,071 -2% -9% 7% 7% 1% -1% Fresenius Helios 2,953 2,829 4% -

  54. Slide 54: Revenue by Business Segment – FX, Acquisitions/Divestitures Effects Q1-3/23

    Revenue by Business Segment – FX, Acquisitions/Divestitures Effects Q1-3/23 Growth at Currency Growth at Divesti- actual translation constant Organic Acquisi- tures/ €m Q1-3/23 Q1-3/22 rates effects rates growth tions Others Fresenius Kabi 6,013 5,814 3% -5% 8% 7% 2% -1% Fresenius Helios 9,132 8,685

  55. Slide 55: Financial Calendar / Contact

    Financial Calendar / Contact Financial Calendar Social Media 21 February 2024 Results FY/23 Follow Fresenius Investor Relations on LinkedIn: 08 May 2024 Results Q1/24 17 May 2024 Annual General Meeting 31 July 2024 Results Q2/24 06 November 2024 Results Q3/24 Please note that these dates could be su

  56. Slide 56: #FutureFresenius

    = FRESENIUS #FutureFresenius—

Fresenius SE & Co. KGaA — UniCredit Kepler Cheuvreux 23rd German Corporate Conference 2024 on 6ix